Swedbank Has Cut Henry Schein (HSIC) Position By $6.08 Million; Diplomat Pharmacy (DPLO) Shorts Up By 17.29%

April 17, 2018 - By Vivian Currie

Diplomat Pharmacy, Inc. (NYSE:DPLO) Logo

Diplomat Pharmacy Inc (NYSE:DPLO) had an increase of 17.29% in short interest. DPLO’s SI was 7.40M shares in April as released by FINRA. Its up 17.29% from 6.31 million shares previously. With 1.03 million avg volume, 7 days are for Diplomat Pharmacy Inc (NYSE:DPLO)’s short sellers to cover DPLO’s short positions. The SI to Diplomat Pharmacy Inc’s float is 14.9%. The stock increased 5.43% or $1.1 during the last trading session, reaching $21.35. About 823,144 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has risen 34.38% since April 17, 2017 and is uptrending. It has outperformed by 22.83% the S&P500.

Swedbank decreased Henry Schein Inc (HSIC) stake by 3.74% reported in 2017Q4 SEC filing. Swedbank sold 88,149 shares as Henry Schein Inc (HSIC)’s stock declined 8.35%. The Swedbank holds 2.27M shares with $158.66 million value, down from 2.36M last quarter. Henry Schein Inc now has $10.95 billion valuation. The stock increased 1.42% or $0.99 during the last trading session, reaching $70.93. About 443,621 shares traded. Henry Schein, Inc. (NASDAQ:HSIC) has declined 24.00% since April 17, 2017 and is downtrending. It has underperformed by 35.55% the S&P500.

Investors sentiment increased to 1.89 in 2017 Q4. Its up 0.45, from 1.44 in 2017Q3. It improved, as 17 investors sold Diplomat Pharmacy, Inc. shares while 40 reduced holdings. 45 funds opened positions while 63 raised stakes. 47.12 million shares or 4.65% less from 49.42 million shares in 2017Q3 were reported. Parkside Fincl Bank And Tru reported 1,610 shares or 0.01% of all its holdings. Fifth Third Bancorp has 0% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 1,917 shares. Continental Advsrs Lc has invested 0.19% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Louisiana State Employees Retirement has 0.02% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO). The New Jersey-based Prudential Fincl Inc has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Tiaa Cref Investment Mgmt Ltd Limited Liability Company stated it has 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Sivik Glob Healthcare Limited Liability Company has invested 0.74% in Diplomat Pharmacy, Inc. (NYSE:DPLO). 60,515 were reported by Chicago Equity Prtnrs Lc. Victory Cap Mgmt invested 0.02% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Stifel Finance invested in 67,376 shares or 0% of the stock. Wells Fargo & Communication Mn has 0% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 90,104 shares. Citadel Advisors Limited Liability Company has 10,533 shares. Virginia Retirement Et Al reported 97,300 shares. Moreover, Pdt Prtnrs Ltd Liability Co has 0.13% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO). Bnp Paribas Arbitrage Sa accumulated 0% or 24,371 shares.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.58 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 93.64 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Among 15 analysts covering Diplomat Pharmacy (NYSE:DPLO), 6 have Buy rating, 0 Sell and 9 Hold. Therefore 40% are positive. Diplomat Pharmacy had 45 analyst reports since August 4, 2015 according to SRatingsIntel. Mizuho maintained Diplomat Pharmacy, Inc. (NYSE:DPLO) rating on Tuesday, November 7. Mizuho has “Hold” rating and $20.0 target. The rating was maintained by Robert W. Baird on Monday, September 18 with “Outperform”. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) earned “Neutral” rating by Mizuho on Thursday, November 3. The rating was maintained by Cowen & Co with “Market Perform” on Thursday, November 3. As per Friday, February 2, the company rating was downgraded by Deutsche Bank. The firm has “Outperform” rating by Leerink Swann given on Tuesday, February 27. The firm earned “Market Perform” rating on Tuesday, November 7 by Leerink Swann. Raymond James downgraded Diplomat Pharmacy, Inc. (NYSE:DPLO) on Thursday, November 3 to “Market Perform” rating. Leerink Swann upgraded the stock to “Outperform” rating in Monday, December 11 report. The firm has “Hold” rating by Credit Suisse given on Thursday, January 25.

Since March 9, 2018, it had 0 insider buys, and 1 sale for $44.40 million activity. Another trade for 2.15M shares valued at $44.40M was sold by Hagerman Philip R.

Swedbank increased Gilead Sciences (NASDAQ:GILD) stake by 143,525 shares to 1.93M valued at $138.29 million in 2017Q4. It also upped Adobe Systems In (NASDAQ:ADBE) stake by 57,448 shares and now owns 1.60 million shares. Take (NASDAQ:TTWO) was raised too.

Analysts await Henry Schein, Inc. (NASDAQ:HSIC) to report earnings on May, 8. They expect $0.92 earnings per share, up 4.55% or $0.04 from last year’s $0.88 per share. HSIC’s profit will be $141.96 million for 19.27 P/E if the $0.92 EPS becomes a reality. After $0.97 actual earnings per share reported by Henry Schein, Inc. for the previous quarter, Wall Street now forecasts -5.15% negative EPS growth.

Among 22 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 11 have Buy rating, 1 Sell and 10 Hold. Therefore 50% are positive. Henry Schein Inc. had 50 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Tuesday, November 7 by Leerink Swann. Jefferies maintained Henry Schein, Inc. (NASDAQ:HSIC) on Friday, October 20 with “Hold” rating. The rating was maintained by Robert W. Baird on Thursday, October 19 with “Buy”. Barrington Research maintained Henry Schein, Inc. (NASDAQ:HSIC) on Wednesday, February 22 with “Outperform” rating. Gabelli upgraded Henry Schein, Inc. (NASDAQ:HSIC) on Tuesday, January 10 to “Buy” rating. As per Friday, December 8, the company rating was initiated by Deutsche Bank. The stock of Henry Schein, Inc. (NASDAQ:HSIC) has “Hold” rating given on Wednesday, September 27 by Jefferies. Stifel Nicolaus maintained it with “Hold” rating and $89.0 target in Tuesday, October 17 report. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, August 8 report. Piper Jaffray maintained Henry Schein, Inc. (NASDAQ:HSIC) rating on Tuesday, August 8. Piper Jaffray has “Hold” rating and $19000 target.

Investors sentiment decreased to 0.83 in Q4 2017. Its down 6.32, from 7.15 in 2017Q3. It fall, as 72 investors sold HSIC shares while 170 reduced holdings. 62 funds opened positions while 139 raised stakes. 146.17 million shares or 47.74% less from 279.70 million shares in 2017Q3 were reported. Brown Advisory Inc reported 0.13% in Henry Schein, Inc. (NASDAQ:HSIC). State Common Retirement Fund holds 1.49 million shares or 0.13% of its portfolio. Northern Tru invested in 2.01 million shares. Virtus Inv Advisers has invested 0.01% in Henry Schein, Inc. (NASDAQ:HSIC). Raymond James & Assoc holds 0.02% or 144,090 shares in its portfolio. Atlanta Mgmt L L C reported 2.46M shares stake. Sheets Smith Wealth has 1.29% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 78,560 shares. Qs Ltd Liability Company invested in 8,646 shares. Amp Investors Ltd reported 45,126 shares. Mufg Americas Holdg owns 0.02% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 8,434 shares. 59,109 are owned by Citadel Limited Com. Andra Ap holds 0.24% or 152,101 shares in its portfolio. Ntv Asset Mgmt Limited Liability Company accumulated 3,300 shares. Gamco Investors Incorporated Et Al accumulated 275,628 shares. Captrust Financial Advsr has invested 0.01% in Henry Schein, Inc. (NASDAQ:HSIC).

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: